ReportsnReports.com adds Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity to its online market intelligence reports library. Dallas, Texas (PRWEB) December 21, 2012 The growth in the APAC stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nations economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohns disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research. Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to this research and analysis of the stem cell therapy research in Asia-Pacific, … Continue reading →

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,318,485 by the United States Patent and Trademark Office. This broad-based patent covers the treatment of diabetic retinopathy and other degenerative diseases of the eye with the Companys ischemic tolerant neural (itNSC) and mesenchymal (itMSC) stem cells. San Diego, CA (PRWEB) December 20, 2012 In the United States, diabetic retinopathy is the leading cause of new blindness in people 25-74 years of age. Approximately 700,000 persons in the United States have proliferative diabetic retinopathy. Each year another 65,000 are diagnosed with the condition. A recent study has estimated that, among people with diabetes aged 40 or older, 28.5% will develop diabetic retinopathy. Worldwide, it is estimated that 20 million people have proliferative diabetic retinopathy, with this number projected to increase to over 30 million by 2030. Diabetic retinopathy begins as a vascular condition with microaneurysms in the vessels of the retina. These blood vessels become blocked, thereby depriving portions of the retina from blood supply. This trauma causes the retina to secrete vascularization signals that result in new, fragile, abnormal blood vessels being formed. The … Continue reading →

Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps Research Institute to investigate the role of Stemedicas ischemia tolerant human mesenchymal stem cells and stem cell factors as a therapy for severe lung injury and sepsis. San Diego, CA (PRWEB) December 21, 2012 Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are the most common causes of respiratory failure among critically ill patients. The mortality for this syndrome remains high at 30-40% and accounts for approximately 75,000 deaths per year. Severe bacterial pneumonia is the most common cause of ALI/ARDS and is frequently associated with septic shock. The only intervention for ALI/ARDS that has resulted in a mortality benefit is low tidal volume ventilation. Despite several attempts, there have been no pharmacological agents that have reduced the morbidity or mortality from ALI/ARDS. Furthermore, treatment of bacterial pneumonia is increasingly hampered by the rapid spread of multi-drug resistant bacteria and the lack of new antimicrobial agents to treat them. Therefore, given the large public health impact of severe bacterial pneumonia and ALI/ARDS, novel therapies are needed to address this … Continue reading →